Saxagliptin/dapagliflozin is non-inferior to insulin glargine in terms of β-cell function in subjects with latent autoimmune diabetes in adults: A 12-month, randomized, comparator-controlled pilot study.
Ernesto MaddaloniAnda M NaciuCarmen MignognaRaffaele GalieroRocco AmendolaraMarta FogolariChiara SattaChiara SerafiniSilvia AngelettiMaria Gisella CavalloEfisio CossuFerdinando Carlo SassoRaffaella BuzzettiPozzilli Paolonull nullPublished in: Diabetes, obesity & metabolism (2024)
Saxagliptin/dapagliflozin was non-inferior to glargine in terms of β-cell function in this 12-month, small, phase 2b study, enrolling people with LADA with still viable endogenous insulin production. Weight loss was greater with saxagliptin/dapagliflozin, with no differences in glycaemic control or hypoglycaemic risk.
Keyphrases
- glycemic control
- type diabetes
- weight loss
- bariatric surgery
- double blind
- insulin resistance
- open label
- roux en y gastric bypass
- cardiovascular disease
- gastric bypass
- placebo controlled
- multiple sclerosis
- phase iii
- clinical trial
- metabolic syndrome
- phase ii
- drug induced
- weight gain
- adipose tissue
- obese patients
- skeletal muscle